Degroof Petercam - Home Invest Belgium SA (HOMI) Home Invest Belgium - Optional dividend +6.7% portfolio valuation

Report

Degroof Petercam

Vincent Koppmair

Home Invest Belgium - Optional dividend & +6.7% portfolio valuation

HOMI proposes an optional dividend at an EGM on 24 May.Positive portfolio valuation of 6.7% in Q1 2024.We reiterated our ‘Hold' rating and EUR 18.00 TP.More details in our Note published this morning

25/04/2024 1 EN

Underlying

Home Invest Belgium SA

Home Invest Belgium SA is a public regulated real estate company based in Belgium. The Company specializes in the acquisition, sale, development and management of residential real estate properties. It holds a wide portfolio of properties located on strategic locations in Belgium and The Netherlands. The Comapny's oerates throught its subsidiares such as Clarestates BV.

See profile

BE0003760742 Euronext Brussels Belgium

Provider

Degroof Petercam

We are an investment house with Belgian roots founded on more than 150 years of trust.

As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.

See profile

Analysts

Vincent Koppmair

Other Reports on these Companies

Degroof Petercam

Home Invest Belgium - Q1 2024 - Stellar start to the year

EPRA results is up 12% YoY due to higher rental income and improved operating margin, EPS up 1.5% from the dilution impact of 2023's ABB.LTV down ca. 300bps to 47% due to disposals (EUR 40m) and positive revaluation (+6.7% / EUR +50m).We raise our TP to EUR 20.50 (from EUR 18.00) and upgrade HOMI to ‘Buy' (from ‘Hold'). Our TP implies a 17% upside potential.More details in our Note published this morning

May 23, 2024 May 23, 2024 1 EN

SmartInsider

Home Invest Belgium NV: 1 director

A director at Home Invest Belgium NV bought 1,025,850 shares at 13.080EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The ...

Free Trial

April 24, 2024 April 24, 2024 1 EN

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

Whitestone's NAV almost tripled in size over H1 from EUR 34.4m to EUR 99.7m at June 30.The majority of the immense growth is thanks to two capital raises with in total EUR 59.7m raised.The remainder of the growth comes from the solid performance in the portfolio (+EUR 6m).The company still has more than EUR 20m in cash available to deploy, even after its most recent investment in Lambda X Ophtalmics.We estimate today's NAV at EUR 14.5 p/s implying a discount of 16.5%. Our TP moves to EUR 13.4 (was EUR 13.9) and we reiterate our Hold rating.

October 28, 2024 October 28, 2024 1 EN

David Seynnaeve ... (+2)

David Seynnaeve
PhD

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

*OPM reported the final results of its Ph1 study with RIPK2 inhibitor ‘OPM-101'. Ph1b/2a expected to launch early 2025.*While results look highly encouraging, with strong safety data and no cardiac toxicity, we await clarity on the Ph1b/2a trial protocol and pursued indication.*Our rNPV-based valuation takes into account estimates related to OPM-101 and OPM-201 and does not factor in the potential dilutive impact of any future capital raises. Discovery/preclinical-stage programs are considered upside for the time being. We recommend to Buy the stock considering the attractive 66% upside a...

October 23, 2024 October 23, 2024 1 EN

Luuk Van Beek

Luuk Van Beek

(Sponsored) Cabka - Encouraging sales trend in Q3

Q3-24 sales increased 8% to EUR 42.4m, showing an encouraging sequential trendManagement reiterates its guidance for EUR 180-185m in revenues and a 13-15% EBITDA margin in 2024We will fine-tune our estimates and reiterate our Buy and EUR 4.60 TP

October 21, 2024 October 21, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Home Invest Belgium - Optional dividend & +6.7% portfolio valuation

Home Invest Belgium - Q1 2024 - Stellar start to the year

Home Invest Belgium NV: 1 director

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

(Sponsored) Cabka - Encouraging sales trend in Q3

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe